485
Participants
Start Date
July 30, 2021
Primary Completion Date
February 22, 2024
Study Completion Date
February 27, 2024
Lumateperone
Lumateperone 42 mg capsules administered orally, once daily.
Placebo
Matching capsules administered orally, once daily.
Clinical Site, Budapest
Clinical Site, Budapest
Clinical Site, Budapest
Clinical Site, Vratsa
Clinical Site, Gyöngyös
Clinical Site, Veliko Tarnovo
Clinical Site, Veliko Tarnovo
Clinical Site, Pleven
Clinical Site, Kazanlak
Clinical Site, Rousse
Clinical Site, Burgas
Clinical Site, Tsarev Brod
Clinical Site, Cedarhurst
Clinical Site, Decatur
Clinical Site, Jacksonville
Clinical Site, Orlando
Clinical Site, Fort Lauderdale
Clinical Site, Brno
Clinical Site, Ostrava
Clinical Site, Austin
Clinical Site, Bratislava
Clinical Site, Phoenix
Clinical Site, Glendale
Clinical Site, Upland
Clinical Site, Oceanside
Clinical Site, Redlands
Clinical Site, Temecula
Clinical Site, Ludhiana
Clinical Site, Varanasi
Clinical Site, Lucknow
Clinical Site, Jaipur
Clinical Site, Jūnāgadh
Clinical Site, Ahmedabad
Clinical Site, Vadodara
Clinical Site, Nashik
Clinical Site, Nashik
Clinical Site, Aurangabad
Clinical Site, Nagpur
Clinical Site, Mysore
Clinical Site, Mangaluru
Clinical Site, Kozhikode
Clinical Site, Guwahati
Clinical Site, Boston
Clinical Site, Berlin
Clinical Site, Toms River
Clinical Site, Brno
Clinical site, Pilsen
Clinical Site, Prague
Clinical Site, Prague
Clinical Site, Košice
Clinical Site, Rimavská Sobota
Clinical Site, Svidník
Clinical Site, Vranov nad Topľou
Clinical Site, Zlaté Moravce
Lead Sponsor
Intra-Cellular Therapies, Inc.
INDUSTRY